经颈动脉血运重建术中低频可避免错误分析
基于全球13334例TCAR病例的投诉数据库分析,报告了颈动脉穿刺点夹层(1.4%)、支架误放(0.13%)、颅神经损伤(0.08%)等低频并发症,多数与操作者技术错误相关且可预防。
要点
- TCAR穿刺点夹层总体发生率1.4%,其中24.3%转为CEA,22.5%未干预或仅药物治疗。
- 支架误放发生率0.13%,最常见于颈外动脉(75%),需警惕牛型主动脉弓高位变异。
- 颅神经损伤发生率0.08%,仅1例持续超过3个月,多数可自行恢复。
核心结论
- TCAR在高危颈动脉狭窄患者中安全性良好,但存在低频可避免的操作者技术错误相关并发症。
主要发现
- 颈总动脉穿刺点夹层173例(1.4%),其中22.5%未干预或仅药物治疗,24.3%转为CEA。
- 支架误放16例(0.13%),最常见于颈外动脉(75%),另有1例因牛型主动脉弓高位变异放置至对侧颈动脉。
- 颅神经损伤11例(0.08%),仅1例持续超过3个月;另报告3例气胸和1例乳糜胸。
临床怎么用
- 术中应仔细关注细节以识别并预防穿刺点夹层、支架误放和颅神经损伤等可避免错误。
- 对牛型主动脉弓高位变异患者需特别警惕对侧颈动脉误放支架的风险。
局限性
- 数据来源于厂商投诉数据库,可能低估并发症发生率且缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Transcarotid artery revascularization (TCAR) seems to be a safe and effective alternative to carotid endarterectomy (CEA) and transfemoral carotid artery stenting (TF-CAS). The TCAR system represents a paradigm shift in the management of carotid artery stenosis with potential for a significant decrease in periprocedural morbidity. However, as with CEA or TF-CAS, TCAR is associated with infrequent complications related to user technical error, most of which are preventable. Our goal is to describe these low-frequency events, and to provide guidelines for avoiding them. METHODS: The U.S. Food and Drug Administration (FDA) requires that all medical device manufacturers create a system for receiving, reviewing, and evaluating complaints (Code 21 of Federal Regulations 820.198). Silk Road Medical, Inc (Sunnyvale, Calif), has established a process by which all feedback, including complaints that may not meet FDA criteria, is captured and stored in a database for detailed analysis. More than 13,300 cases have been performed; submitted complaints were reviewed for incidents of serious injury and periprocedural complications, above and beyond the device-related events that must be reported to the FDA. RESULTS: A total of 13,334 patients have undergone TCAR worldwide between early 2011 and December 2019 using the SilkRoad device. Reported complications included 173 dissections (1.4% overall rate) of the common carotid artery at the access point, of which 22.5% were managed without intervention or with medical therapy alone and 24.3% were converted to CEA (considered failing safely). Errors in the location of stent deployment occurred in 16 cases (0.13%), with the most common site being the external carotid artery (75%). One wrong side carotid artery stent was placed in a patient with a high midline pattern of the bovine arch. Cranial nerve injury was reported in 11 cases (0.08%), only one of which persisted beyond 3 months. There have been three reported pneumothoraces and one reported chylothorax. Many of these errors can be recognized and prevented with careful attention to detail. CONCLUSIONS: In high-risk patients requiring treatment for carotid artery stenosis, TCAR has been proven as an alternative to TF-CAS with an excellent safety profile. As with CEA or TF-CAS, this procedure has the potential for infrequent complications, often as a result of user technical error. Although significant, these events can be avoided through a review of the collective experience to date and recognition of potential pitfalls, as we have described.
引用
- Teter K, Lamparello PJ, Barfield M, et al. Low-frequency avoidable errors during transcarotid artery revascularization. J Vasc Surg. 2020. PMID: 33065241. doi:10.1016/j.jvs.2020.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。